Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 6/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 2/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3331190 | 0.91 | NPY5R (0.48) | NPY5RDRD3TNKSTNKS2PRKAA2 | |
| SCHEMBL3344193 | 0.89 | NPY5R (0.47) | NPY5RDRD3ACKR3TNKSTNKS2 | |
| SCHEMBL3344844 | 0.85 | NPY5R (0.47) | NPY5RDRD3 | |
| SCHEMBL3343381 | 0.85 | NPY5R (0.49) | NPY5RDRD3ACKR3TNKSTNKS2 | |
| SCHEMBL3319938 | 0.85 | NPY5R (0.49) | NPY5RDRD3 | |
| SCHEMBL3346374 | 0.84 | TNKS (0.49) | NPY5RDRD3ACKR3TNKSTNKS2 | |
| SCHEMBL3340753 | 0.84 | LMNA (0.50) | NPY5RDRD3JAK1 | |
| SCHEMBL3342660 | 0.84 | DHODH (0.49) | NPY5RDRD3ACKR3 | |
| SCHEMBL10192500 | 0.84 | NPY5R (0.51) | NPY5RDRD3JAK1 | |
| SCHEMBL3325703 | 0.84 | NPY5R (0.51) | NPY5RDRD3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653125-B2 | Cyclohexane derivative having NPY Y5 receptor antagonism | SHIONOGI CO., LTD. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20120004227-A1 | CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM | SHIONOGI & CO., LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004227-A1 | CYCLOHEXANE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISM | NPY5R, NPY1R, NPY2R | NPY5R 1/4885DRD3 342/4885ACKR3 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.